Your browser doesn't support javascript.
loading
Modelling Disease Progression of Multiple Sclerosis in a South Wales Cohort.
Uzochukwu, Emeka C; Harding, Katharine E; Hrastelj, James; Kreft, Karim L; Holmans, Peter; Robertson, Neil P; Tallantyre, Emma C; Lawton, Michael.
Affiliation
  • Uzochukwu EC; Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK.
  • Harding KE; Department of Neurology, Royal Gwent Hospital, Newport, UK.
  • Hrastelj J; Department of Neurology, University Hospital of Wales, Cardiff, UK.
  • Kreft KL; Department of Neurology, University Hospital of Wales, Cardiff, UK.
  • Holmans P; Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK.
  • Robertson NP; Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.
  • Tallantyre EC; Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK.
  • Lawton M; Department of Neurology, University Hospital of Wales, Cardiff, UK.
Neuroepidemiology ; 58(3): 218-226, 2024.
Article in En | MEDLINE | ID: mdl-38377969
ABSTRACT

OBJECTIVES:

The objective of this study was to model multiple sclerosis (MS) disease progression and compare disease trajectories by sex, age of onset, and year of diagnosis. STUDY DESIGN AND

SETTING:

Longitudinal EDSS scores (20,854 observations) were collected for 1,787 relapse-onset MS patients at MS clinics in South Wales and modelled using a multilevel model (MLM). The MLM adjusted for covariates (sex, age of onset, year of diagnosis, and disease-modifying treatments), and included interactions between baseline covariates and time variables.

RESULTS:

The optimal model was truncated at 30 years after disease onset and excluded EDSS recorded within 3 months of relapse. As expected, older age of onset was associated with faster disease progression at 15 years (effect size (ES) 0.75; CI 0.63, 0.86; p <0.001) and female-sex progressed more slowly at 15 years (ES -0.43; CI -0.68, -0.18; p <0.001). Patients diagnosed more recently (defined as 2007-2011 and >2011) progressed more slowly than those diagnosed historically (<2006); (ES -0.46; CI -0.75, -0.16; p 0.006) and (ES -0.95; CI -1.20, -0.70; p <0.001), respectively.

CONCLUSION:

We present a novel model of MS outcomes, accounting for the non-linear trajectory of MS and effects of baseline covariates, validating well-known risk factors (sex and age of onset) associated with disease progression. Also, patients diagnosed more recently progressed more slowly than those diagnosed historically.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Age of Onset / Disease Progression / Multiple Sclerosis Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Neuroepidemiology Year: 2024 Document type: Article Affiliation country: Reino Unido Country of publication: Suiza

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Age of Onset / Disease Progression / Multiple Sclerosis Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Neuroepidemiology Year: 2024 Document type: Article Affiliation country: Reino Unido Country of publication: Suiza